All In Biotech

NDA 021307 · Bayer Healthcare LLC

Lotrimin Ultra

Butenafine Hydrochloride · Topical

Last checked: Nov 19, 2026Latest source record: Jul 10, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2001

Dec 7, 2001

Approved uses

2

Original approval plus efficacy supplements

Registered trials

8

4 Phase 3, 0 recruiting

FAERS reports

578

61 serious, 7 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Dec 5, 2025.

Uses cures most jock itch relieves itching, burning, cracking, and scaling which accompany this condition

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 17, 2014 Supplement 14 · Efficacy Letter
  • Dec 7, 2001 Original approval · Type 8 - Partial Rx to OTC Switch LetterReviewLabel
1 products under this application
  • LOTRIMIN ULTRA · BUTENAFINE HYDROCHLORIDE 1% · CREAM, TOPICAL · Over-the-counter

Clinical trials

Interventional ClinicalTrials.gov studies with "Butenafine" as an intervention, any sponsor and status, largest first.

All 8 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective185
  • off label use59
  • product use issue43
  • product use in unapproved indication34
  • pruritus33
  • condition aggravated29
  • rash21
  • drug ineffective for unapproved indication20
  • drug effective for unapproved indication19
  • erythema19
  • drug effect decreased18
  • product administered at inappropriate site15

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041
20052
20062
20071
20081
20101
20111
201241
201381
201461
201525
201631
201741
201842
201932
202028
202124
202227
202338
202430
202539
202629

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 18 on PubMed

Sponsor: Bayer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.